Cibus (CBUS) Total Current Liabilities (2016 - 2026)
Cibus (CBUS) posted Total Current Liabilities of $16.9 million for Q4 2025, down 17.8% sequentially from $20.6 million in Q3 2025, and down 14.98% YoY from $19.9 million in Q4 2024.
Cibus (CBUS) Total Current Liabilities (2016 - 2026) Analysis & Trends
Cibus has reported Total Current Liabilities for 10 years, with the latest figure at $16.9 million in Q4 2025.
- Quarterly Total Current Liabilities fell 14.98% year-over-year to $16.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.9 million (down 14.98% YoY) and the FY2025 annual result came in at $16.9 million, down 14.98% from the prior year.
- Total Current Liabilities declined to $16.9 million in Q4 2025 per CBUS's latest filing, from $20.6 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $29.0 million in Q2 2024 and troughed at $1.7 million in Q4 2022.
- A 5-year average of $14.5 million and a median of $18.4 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities slumped 65.76% in 2022, then surged 1182.97% in 2023.
- Over 5 years, Total Current Liabilities stood at $4.9 million in 2021, then plunged by 65.76% to $1.7 million in 2022, then soared by 1182.97% to $21.3 million in 2023, then declined by 6.78% to $19.9 million in 2024, then fell by 14.98% to $16.9 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $16.9 million, $20.6 million, and $22.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 630.93 Mn |
| 10 | Cibus | 134.33 Mn | 113.90 Mn | - | 14.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.45 Mn |
| Dec 31, 2025 | 16.90 Mn |
| Sep 30, 2025 | 20.56 Mn |
| Jun 30, 2025 | 22.40 Mn |
| Mar 31, 2025 | 21.00 Mn |
| Dec 31, 2024 | 19.88 Mn |
| Sep 30, 2024 | 21.90 Mn |
| Jun 30, 2024 | 28.97 Mn |
| Mar 31, 2024 | 21.70 Mn |
| Dec 31, 2023 | 21.32 Mn |
| Sep 30, 2023 | 25.10 Mn |
| Jun 30, 2023 | 22.40 Mn |
| Mar 31, 2023 | 4.22 Mn |
| Dec 31, 2022 | 1.66 Mn |
| Sep 30, 2022 | 4.23 Mn |
| Jun 30, 2022 | 4.50 Mn |
| Mar 31, 2022 | 9.50 Mn |
| Dec 31, 2021 | 4.85 Mn |
| Sep 30, 2021 | 5.14 Mn |
| Jun 30, 2021 | 7.16 Mn |